Shuo Shao

Shuo Shao

Auto-generated profile, based on publicly available information

Shuo Shao

Department of Radiology, Jining NO. 1 Peoples Hospital Affiliated to Shandong First Medical University, Jining, Shandong, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in British Journal of Radiology
Verified
Journal Article
Closed access
NZNing Zheng
Ning Zheng
RLRui Li
Rui Li
WLWenjuan Liu
Wenjuan Liu
SSShuo Shao
Shuo Shao
SJShan Jiang
Shan Jiang
Objective:To determine the diagnostic value of combining conventional MRI, diffusion-weighted imaging (DWI) and dynamic contrast enhanced MRI (DCE-MRI) in salivary gland tumors.Methods:45 patients ...

28 June 2020 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
SSShuo Shao
Shuo Shao
YLYingying Liang
Yingying Liang
SKSichi Kuang
Sichi Kuang
JCJingbiao Chen
Jingbiao Chen
QSQungang Shan
Qungang Shan
CSClaude B. Sirlin
Claude B. Sirlin
The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study was to evaluate the accuracy of the LI-RADS version 2018 in differentiating HCC, intrahepatic cholangiocarcinoma (ICCA), and combined HCC-cholangiocarcinoma (cHCC-CCA) in Chinese patients with HBV infection. Seventy consecutive HBV-infected patients with ICCA (n = 48) or cHCC-CCA (n = 22) who underwent contrast-enhanced magnetic resonance imaging (CE-MRI) between 2006 and 2017 were enrolled along with a comparison cohort of 70 patients with HCC and CE-MRI-matched for tumor size (10–19 mm, 20–30 mm, 31–50 mm, and >50 mm). Imaging feature frequencies for each tumor type were compared using Fisher’s exact test. The classification accuracy of LR-5 and LR-M was estimated for HCC versus non-HCC (ICCA and cHCC-CCA). The interobserver agreement was good for LI-RADS categories of HCC and moderate for non-HCC. After consensus read, 66 of 70 (94%) HCCs were categorized LR-5 (including tumor in vein [TIV] with LR-5), while 42 of 48 (88%) ICCAs and 13 of 22 (59%) cHCC-CCAs were categorized LR-M (including TIV with LR-M) (p < 0.001). Thus, assignment of LR-5 provided 94% sensitivity and 81% specificity for HCC. LR-M provided 79% sensitivity and 97% specificity for non-HCC (ICCA and cHCC-CCA); and the sensitivity and accuracy were lower in differentiating HCC from non-HCC (tumor size <20 mm). LI-RADS v2018 category 5 and M reliably differentiated HBV-related HCC from ICCA. However, a substantial proportion of cHCC-CCAs were categorized LR-5 rather than LR-M. While management is controversial for these combined tumors, accurate prospective differentiation is desired for optimal treatment.

10 August 2021 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
JCJingfeng Cheng
Jingfeng Cheng
SSShuo Shao
Shuo Shao
WCWeibo Chen
Weibo Chen
NZNing Zheng
Ning Zheng

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
YLYing-Ying Liang
Ying-Ying Liang
SSShuo Shao
Shuo Shao
SKSichi Kuang
Sichi Kuang
JCJingbiao Chen
Jingbiao Chen
JZJing Zhou
Jing Zhou
JWJin Wang
Jin Wang
Purpose. To describe liver imaging reporting and data system (LI‐RADS) version 2018 and other MRI imaging features in intrahepatic mass‐forming cholangiocarcinoma (iCCA) in Chinese adults with vs. without chronic hepatitis B viral (HBV) infection. Methods. We retrospectively enrolled 89 patients with pathologically proven iCCA after multiphase imaging performed between 2004 and 2017 at a tertiary medical center in southern China. Based on whether patients had chronic HBV, iCCA was divided into two subgroups: HBV‐positive (n = 50 patients, including 9 with cirrhosis) vs. HBV‐negative (n = 39 patients, including 14 with hepatolithiasis and 25 with no identifiable risk factor for iCCA; none had cirrhosis). Two independent abdominal radiologists in consensus reviewed the largest mass in each patient to assign LI‐RADS v2018 features; they also scored each observation’s shape and location. Imaging features were compared using chi‐square or Fisher’s exact tests. Results. Most iCCAs in HBV‐positive (88% (44/50)) and HBV‐negative (97% (38/39)) patients had at least one LR‐M feature. Compared to iCCAs in HBV‐negative patients, iCCAs in HBV‐positive patients were more likely to have at least one major feature of HCC (46% (23/50) vs. 8% (3/39), P < 0.001) and more likely to be smooth (42% (21/50) vs. 10% (4/39), P = 0.001). Six of 50 (12%) iCCAs in HBV‐positive patients and 1/39 (3%) iCCAs in HBV‐negative patients had at least one major feature of HCC without any LR‐M feature. Conclusions. In this retrospective single‐center study in Chinese adults, iCCAs in HBV‐positive patients were more likely to resemble HCCs than iCCAs in HBV‐negative patients.

16 May 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
HHHuimin Huang
Huimin Huang
NZNing Zheng
Ning Zheng
LFLei Feng
Lei Feng
SSShuo Shao
Shuo Shao
Moyamoya disease (MMD), a chronic, progressive cerebrovascular disorder of unknown etiology, presents significant diagnostic and therapeutic challenges in clinical practice. Conventional diagnostic methods rely on physicians’ experience and have limitations in disease prediction, risk assessment, and treatment decisions. The advancement of artificial intelligence (AI) technologies has created new opportunities for research on MMD. This review summarizes recent advances in AI applications for MMD, including diagnosis, risk factor analysis, treatment planning, outcome evaluation, and basic research. Additionally, this review critically examines the limitations of current research on MMD and explores potential future directions, aiming to offer valuable insights and guidance on MMD.

6 October 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QWQingxue Wang
Qingxue Wang
NZNing Zheng
Ning Zheng
QYQing-Qing Yu
Qing-Qing Yu
SSShuo Shao
Shuo Shao
HER-2-positive breast cancer is a biologically distinct subtype, accurate early assessment of HER-2 status is therefore critical for guiding personalized treatment. Currently mainly detected through immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on biopsy or surgical specimens. However, these methods are invasive, susceptible to sampling errors, and lack the capability for real-time, noninvasive monitoring of tumor heterogeneity or treatment response. Therefore, the development of noninvasive imaging-based predictive methods has gained significant research interest. Multiparametric magnetic resonance imaging (mpMRI) can quantify tumor perfusion parameters (Ktrans-vascular permeability, Ve- extracellular space) through dynamic contrast-enhanced MRI (DCE-MRI), measure the apparent diffusion coefficient (ADC) using diffusion-weighted imaging (DWI), and obtain metabolic information via positron emission tomography-MRI (PET-MRI), which are closely associated with HER-2 expression status. Concurrently, radiomics and deep learning (DL) systematically extract multidimensional features of breast tumors from multimodal imaging data, including morphological parameters (sphericity, surface area), first-order statistical metrics (kurtosis, K; skewness), and textural features (gray-level co-occurrence matrix GLCM, quantisation texture space distribution; gray-level run-length matrix GLRLM, evaluation of homogeneous region size), thereby constructing high-dimensional quantitative analysis datasets. Based on the resolution of the heterogeneity of the feature spatial distribution, the DL algorithms can autonomously mine the potential imaging patterns closely related to the expression of HER-2 molecules and establish a non-invasive prediction model. Although traditional single-parameter models, such as the ADC derived from DWI, can provide valuable information about the tumor microenvironment, their predictive efficacy is often constrained by parameter inconsistencies and a lack of standardization. As a narrative review, this article argues that multimodal imaging, radiomics, and deep learning are better equipped to capture the complex HER-2-related tumor heterogeneity, thereby providing a stronger theoretical foundation for guiding personalized treatment strategies and prognostic evaluation.